The Age of Diagnosis summary

Some diagnoses begin with a lab result; others grow from stories, symptoms, and a search for meaning. Take Lyme disease. Years of unexplained illness in Lyme, Connecticut, prompted investigation in 1975 and, in 1982, the culprit bacterium was identified in deer ticks. From there, a clear early picture – bullseye rash, flu-like illness – blurred into a wide constellation of complaints across joints, nerves, and the heart.

Testing has never fully fixed the blur. Standard practice uses two-stage antibody testing, but these look for an immune response, not the organism. Results shift with timing, geography, and lab methods, and antibodies can signal past exposure without disease, as seen in forestry workers with high positivity yet few symptoms. Guidelines insist that results be weighed against the full clinical story, because pretest probability matters.

Autism diagnoses have soared in recent decades – not because of a hidden epidemic, but because of shifting definitions, evolving clinical practice, and powerful cultural incentives. Understanding that mix is essential if we want to support people well without losing sight of those who need the most help.

There’s no blood test or scan for autism. Diagnosis depends on observed social communication difficulties, along with repetitive or restricted behaviors that start early in life and cause real impairment. Over time, that picture has broadened. What was once a narrow profile of severe social withdrawal is now understood as a spectrum that includes milder traits. Recent diagnostic manuals have merged subtypes into a single category, recognized that early signs can be masked or missed, and added sensory traits as a core component. With those changes, prevalence in the US has risen from about 4 in 10,000 children to about 1 in 36. Adult diagnoses are going up too, and the gender gap is narrowing.

Cancer genetics promises answers, but what it really delivers is probabilities. Take BRCA1 and BRCA2: they’re repair genes that normally protect us. But certain variants can raise lifetime breast cancer risk from about 12 percent to as high as 85 percent, and ovarian cancer risk from about 2 percent to 60 percent. These numbers don’t guarantee disease, but they do raise the stakes – pushing healthy people to face life-changing decisions long before any symptom appears.

Roisin’s story shows how those choices play out in real life. After watching her mother battle multiple cancers and losing her grandmother, she tested positive for a high-risk BRCA1 variant at just 25. Within months, she chose to have a double mastectomy, and later surgery to remove her ovaries and fallopian tubes. That meant sudden menopause and lasting effects on her body image, sexuality, and relationships. The surgeries cut her cancer risk by about 95 percent, and she feels less haunted now. But she’s also candid about the fear and family pressure that drove her decisions, the patchy psychological support along the way, and the fact that uncertainty never disappears completely.

An ADHD diagnosis can feel like a breakthrough – finally a way to explain years of distractibility, impulsivity, low mood, and exhaustion. It can unlock services and support. But it also leaves gaps. Medication may sharpen focus, and workplaces can cut noise or interruptions, yet performance still wobbles and people often struggle to explain what really helps. Years of “masking”– hiding fidgeting, pushing down impulses, performing competence – take their toll. A label can reframe that strain, but it doesn’t restore energy overnight.

The definition itself has stretched. ADHD once meant tightly defined childhood patterns; now broader adult criteria include milder traits with fuzzy thresholds. Assessment relies heavily on interviews and self-report, so context and expectations shape outcomes as much as rating scales. Co-occurring conditions are common, and regional differences in diagnosis highlight just how subjective the process can be.

When a child’s development is clearly off-track but no cause can be found, doctors sometimes use a placeholder: syndrome without a name, or SWAN. It signals real difficulty but doesn’t explain much, and it shows how heavily access to care and education still depends on having a recognized label. Sequencing is fast today, but understanding lags behind.

Whole-genome sequencing took off after 2005 with next-generation methods. Now an entire genome can be analyzed in about a day for under $1,000. The UK’s large-scale program, launched in 2012, gave firm diagnoses to about 1 in 5 people with unexplained conditions. That’s progress – but ultra-rare answers often explain symptoms without offering treatment, prognosis, or even a peer community. This results in limited practical value.